Nicox will present NCX 470 data at the 2026 AAOpt annual meeting
The ophthalmology laboratory based in Biot announced that it would present scientific data on its NCX 470 candidate at the annual meeting of the American Academy of Optometry, scheduled for September 30 to October 3, 2026 in Anaheim, United States.
This communication is part of a schedule of participation in several ophthalmology, financial and industry conferences in the second half of 2026.
Nicox detailed two presentations scheduled for October 1, 2026 in Anaheim. The first, an oral presentation, will focus on the American subgroup of the Denali trial, a randomized trial comparing NCX 470 0.1% to latanoprost 0.005% in patients with open-angle glaucoma or ocular hypertension.
The second, a poster, will address the aqueous humor dynamics of NCX 470, as part of a phase 3b double-blind, placebo-controlled clinical trial. For the oral presentation, the speaker will be Nora Cothran, optometrist. For the poster, the speaker will be Siobhan Garbutt, Vice President and Director of Clinical Development of the company.
A conference schedule for the second half of 2026
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The company specified that data from its Denali, Whistler and Mont Blanc clinical trials had already been presented at several ophthalmology conferences. According to Siobhan Garbutt, the AAOpt represents an opportunity to share this data directly with the optometry community, involved in the diagnosis and management of glaucoma.
Nicox also announced its participation in the American Academy of Ophthalmology meeting (October 9-12, 2026 in New Orleans) and the Investor Access event (October 6-7, 2026 in Paris), with individual meetings offered to participants.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 3,5 millions d'euros
Quarterly revenue: 3,5 millions d'euros
Revenue growth: 132,2 %
Net income: -0,5 millions d'euros
Guidance from the release
« La Société entend poursuivre au second semestre 2026 la stratégie suivante » ; « la Société estime disposer, à la date du présent rapport, d'une visibilité de trésorerie de plus de 12 mois »
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
